Familial hypercholesterolemia in childhood : diagnostics , therapeutical options and risk stratification

Studies on the clinical consequences of different low-density lipoprotein (LDL) receptor genotypes in adult patients have yielded conflicting results. We hypothesized that children with familial hypercholesterolemia (FH) provide a better model to perform genotype—phenotype analyses than adults. We tested this hypothesis and assessed the effect of LDL receptor genotypes on lipoprotein levels and on parental risk of cardiovascular disease (CVD) in a pediatric FH cohort. We identified 75 different LDL receptor mutations in 645 children with heterozygous FH; in these children, null alleles were clearly associated with more elevated LDL cholesterol levels compared to receptordefective mutations. Familial factors explained 50.4% of the variation in LDL cholesterol levels of this pediatric cohort compared to only 9.5% in adults. Parental CVD risk was not significantly different between carriers of null alleles and receptor-defective mutations (RR, 1.22; 95% CI, 0.76-1.95;/» = 0.4). The N543H/2393del9 mutation was associated with a less deteriorated lipid profile and the parents had less often CVD relative to parents with other mutations (RR, 0.39; 95% CI, 0.20-0.78;/ = 0.008). We could confirm that children with FH provide a better model to perform genotype—phenotype analyses. In particular, children with null alleles had significantly more elevated LDL cholesterol levels than carriers of other alleles but this was not associated with higher risk of CVD in the parents. Nonetheless, a specific LDL receptor mutation was associated with less deteriorated lipoprotein levels and a milder CVD risk.

[1]  J. Kastelein,et al.  The molecular basis of familial hypercholesterolemia in The Netherlands , 2001, Human Genetics.

[2]  J J Kastelein,et al.  Mortality over two centuries in large pedigree with familial hypercholesterolaemia: family tree mortality study. , 2001, BMJ : British Medical Journal.

[3]  E. Sijbrands,et al.  Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands , 2001, The Lancet.

[4]  I. Rabbone,et al.  Clinical Expression of Familial Hypercholesterolemia in Clusters of Mutations of the LDL Receptor Gene That Cause a Receptor-Defective or Receptor-Negative Phenotype , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[5]  R. Westendorp,et al.  Additional risk factors influence excess mortality in heterozygous familial hypercholesterolaemia. , 2000, Atherosclerosis.

[6]  J. Després,et al.  Contribution of receptor negative versus receptor defective mutations in the LDL-receptor gene to angiographically assessed coronary artery disease among young (25-49 years) versus middle-aged (50-64 years) men. , 1999, Atherosclerosis.

[7]  S. Bertolini,et al.  Analysis of LDL receptor gene mutations in Italian patients with homozygous familial hypercholesterolemia. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[8]  Tonstad,et al.  Carotid intima–media thickness and plaque in patients with familial hypercholesterolaemia mutations and control subjects , 1998, European journal of clinical investigation.

[9]  R. Westendorp,et al.  Similar response to simvastatin in patients heterozygous for familial hypercholesterolemia with mRNA negative and mRNA positive mutations. , 1998, Atherosclerosis.

[10]  J. Després,et al.  Heterozygous familial hypercholesterolemia in children: low-density lipoprotein receptor mutational analysis and variation in the expression of plasma lipoprotein-lipid concentrations. , 1996, Atherosclerosis.

[11]  D. Rubinsztein,et al.  Two novel point mutations causing receptor-negative familial hypercholesterolemia in a South African Indian homozygote. , 1996, Atherosclerosis.

[12]  A. Soutar,et al.  Characterization of a splice-site mutation in the gene for the LDL receptor associated with an unpredictably severe clinical phenotype in English patients with heterozygous FH. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[13]  K. Kontula,et al.  Heterozygous familial hypercholesterolaemia: the influence of the mutation type of the low‐density‐lipoprotein receptor gene and PvuII polymorphism of the normal allele on serum lipid levels and response to lovastatin treatment , 1995, Journal of internal medicine.

[14]  O. Faergeman,et al.  The Trp23-Stop and Trp66-Gly mutations in the LDL receptor gene: common causes of familial hypercholesterolemia in Denmark. , 1994, Atherosclerosis.

[15]  G. Coetzee,et al.  Phenotypic variation among familial hypercholesterolemics heterozygous for either one of two Afrikaner founder LDL receptor mutations. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[16]  M. Brown,et al.  A receptor-mediated pathway for cholesterol homeostasis. , 1986, Science.

[17]  L. Bolund,et al.  Two mutations in the same low‐density lipoprotein receptor allele act in synergy to reduce receptor function in heterozygous familial hypercholesterolemia , 1997, Human mutation.

[18]  I. Young,et al.  Three novel mutations in the EGF precursor homology domain of the low‐density lipoprotein receptor gene in Northern Irish patients with familial hypercholesterolemia , 1995, Human mutation.

[19]  H. Hobbs,et al.  Molecular genetics of the LDL receptor gene in familial hypercholesterolemia , 1992, Human mutation.